Uriot Ophélie, Deschamps Charlotte, Scanzi Julien, Brun Morgane, Kerckhove Nicolas, Dualé Christian, Fournier Elora, Durif Claude, Denis Sylvain, Dapoigny Michel, Langella Philippe, Alric Monique, Etienne-Mesmin Lucie, Stéphanie Blanquet-Diot
UMR 454 MEDIS, Microbiologie Environnement Digestif et Santé, Université Clermont Auvergne - INRAE, Clermont-Ferrand, Puy-de-Dôme,France.
UMR INSERM 1107 NEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, Puy-de-Dôme,France.
Bioengineered. 2025 Dec;16(1):2458362. doi: 10.1080/21655979.2025.2458362. Epub 2025 Feb 4.
Irritable bowel syndrome (IBS) is a common chronic gastrointestinal disorder, with diarrhea-predominant IBS (IBS-D) as the most frequent subtype. The implication of gut microbiota in the disease's etiology is not fully understood. gut systems can offer a great alternative to assays in preclinical studies, but no model reproducing IBS-related dysbiotic microbiota has been developed. Thanks to a large literature review, a new Mucosal ARtifical COLon (M-ARCOL) adapted to IBS-D physicochemical and nutritional conditions was set-up. To validate the model and further exploit its potential in a mechanistic study, fermentations were performed using bioreactors inoculated with stools from healthy individuals ( = 4) or IBS-D patients ( = 4), when the M-ARCOL was set-up under healthy or IBS-D conditions. Setting IBS-D parameters in M-ARCOL inoculated with IBS-D stools maintained the key microbial features associated to the disease , validating the new system. In particular, compared to the healthy control, the IBS-D model was characterized by a decreased bacterial diversity, together with a lower abundance of and , but a higher level of and . Of interest, applying IBS-D parameters to healthy stools was not sufficient to trigger IBS-D dysbiosis and applying healthy parameters to IBS-D stools was not enough to restore microbial balance. This validated IBS-D colonic model can be used as a robust platform for studies focusing on gut microbes in the absence of the host, as well as for testing food and microbiota-related interventions aimed at personalized restoration of gut microbiota eubiosis.
肠易激综合征(IBS)是一种常见的慢性胃肠疾病,其中腹泻型肠易激综合征(IBS-D)是最常见的亚型。肠道微生物群在该疾病病因中的作用尚未完全明确。肠道系统可为临床前研究中的检测提供很好的替代方法,但尚未开发出能重现与IBS相关的微生物群落失调的模型。通过大量文献综述,建立了一种适应IBS-D理化和营养条件的新型黏膜人工结肠(M-ARCOL)。为了验证该模型并在机制研究中进一步挖掘其潜力,当M-ARCOL在健康或IBS-D条件下建立时,使用接种了健康个体(n = 4)或IBS-D患者(n = 4)粪便的生物反应器进行发酵。在接种IBS-D粪便的M-ARCOL中设置IBS-D参数可维持与该疾病相关的关键微生物特征,从而验证了这个新系统。特别是,与健康对照相比,IBS-D模型的特点是细菌多样性降低,同时[具体细菌名称1]和[具体细菌名称2]的丰度较低,但[具体细菌名称3]和[具体细菌名称4]的水平较高。有趣的是,将IBS-D参数应用于健康粪便不足以引发IBS-D微生物群落失调,而将健康参数应用于IBS-D粪便也不足以恢复微生物平衡。这个经过验证的IBS-D结肠模型可作为一个强大的平台,用于在无宿主的情况下专注于肠道微生物的研究,以及用于测试旨在个性化恢复肠道微生物群正常状态的食品和与微生物群相关的干预措施。